| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 0 | 3.330 | 1.519 | 3.721 | 7.017 | 7.318 | 6.444 | 6.465 |
| Total Income - EUR | - | - | 0 | 3.330 | 1.519 | 3.721 | 7.017 | 7.318 | 6.444 | 6.465 |
| Total Expenses - EUR | - | - | 0 | 164 | 258 | 44 | 362 | 379 | 1.020 | 872 |
| Gross Profit/Loss - EUR | - | - | 0 | 3.166 | 1.261 | 3.677 | 6.654 | 6.938 | 5.423 | 5.594 |
| Net Profit/Loss - EUR | - | - | 0 | 3.066 | 1.216 | 3.566 | 6.448 | 6.724 | 4.681 | 4.716 |
| Employees | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Check the financial reports for the company - Flamingo Laboratories Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | 44 | 3.205 | 4.363 | 7.790 | 14.252 | 10.711 | 9.768 | 9.138 |
| Inventories | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | 0 | 0 | 0 | 0 | 0 | 161 | 80 | 382 |
| Cash | - | - | 44 | 3.205 | 4.363 | 7.790 | 14.252 | 10.550 | 9.687 | 8.756 |
| Shareholders Funds | - | - | 44 | 3.113 | 4.268 | 7.753 | 14.029 | 10.123 | 9.280 | 8.482 |
| Social Capital | - | - | 44 | 47 | 46 | 45 | 0 | 0 | 44 | 44 |
| Debts | - | - | 15 | 92 | 95 | 37 | 223 | 588 | 488 | 656 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8623 - 8623" | |||||||||
| CAEN Financial Year |
8623
|
|||||||||
Comments - Flamingo Laboratories Srl